Antibodies to soluble liver antigen/liver pancreas and HLA risk factors for type 1 autoimmune hepatitis
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Antibodies to soluble liver antigen/liver-pancreas are highly specific markers of type 1 autoimmune hepatitis that have been associated with relapse. Our aim was to determine if these antibodies are reflective of a genetic predisposition for recrudescent disease. METHODS: One hundred forty-four white North American patients were evaluated by an enzyme immunoassay and by Western blot using recombinant soluble liver antigen/liver-pancreas; 122 were assessed for class II human leukocyte antigens (HLAs). RESULTS: Twenty-two patients (15%) had antibodies to soluble liver antigen/liver-pancreas. These patients were indistinguishable from seronegative patients by clinical, laboratory, and histological features at presentation. Patients with antibodies to soluble liver antigen/liver pancreas had HLA DR3 (79% vs 50%, p = 0.02) more commonly and HLA DR4 less often (16% vs 47%, p = 0.02) than patients with smooth muscle antibodies and/or antinuclear antibodies. Seropositivity was associated with DRB1*0301 and seronegativity was associated with DRB1*0401. Relapse after drug withdrawal occurred in all patients with antibodies to soluble liver antigen/liver-pancreas and at a higher frequency than in patients with conventional antibodies (100% vs 78%, p = 0.05). CONCLUSIONS: Antibodies to soluble liver antigen/liver pancreas are associated with HLA DR3 and the susceptibility allele, DRB1*0301. Antibodies to soluble liver antigen/liver-pancreas may be surrogate markers of a genetic propensity for recrudescent disease or the target autoantigen. They may be complementary to antinuclear antibodies and smooth muscle antibodies in diagnosis and management.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Alvarez, F., Berg, P. A., Bianchi, F. B., Bianchi, L., Burroughs, A. K., Cancado, E. L., Chapman, R. W., Cooksley, W. G. E., Czaja, A. J., Desmet, V. J., et al. (1999) · Journal of Hepatology · doi:10.1016/s0168-8278(99)80297-9 · Cited by 2,903
Self-citationFrequency and nature of cytokine gene polymorphisms in type 1 autoimmune hepatitis
Cookson, S., Constantini, P. K., Clare, M., Underhill, J. A., Bernal, W., Czaja, A. J., & Donaldson, P. T. (1999) · Hepatology · doi:10.1002/hep.510300412 · Cited by 180 · cited 1×
“DRB1*0301 and DRB1*0401 may influence disease occurrence and severity by affecting autoantigen presentation (29, 30, 36, 37) and/or by synergizing with other autoimmune promoters, such as polymorphisms for tumor necrosis factor (38, 39) and cytotoxic T-lymphocyte antigen 4 (40).”
BackgroundSelf-citation
Cited by
Diagnosis and management of autoimmune hepatitis
Manns, M. P., Czaja, A. J., Gorham, J. D., Krawitt, E. L., Mieli-Vergani, G., Vergani, D., & Vierling, J. M. (2010) · Hepatology · doi:10.1002/hep.23584 · Cited by 1,442
Self-citationEASL Clinical Practice Guidelines: autoimmune hepatitis
(2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.06.030 · Cited by 1,245
“Its presence may identify patients with more severe disease and worse outcome [49,50,133,134] though these prognostic associations are controversial [129,132].”
BackgroundMack, C. L., Adams, D., Assis, D. N., Kerkar, N., Manns, M. P., Mayo, M. J., Vierling, J. M., Alsawas, M., Murad, M. H., & Czaja, A. J. (2020) · Hepatology · doi:10.1002/hep.31065 · Cited by 983
“SLA Sep (O-phosphoserine) transfer RNA:Sec (selenocysteine) transfer RNA synthase((560-564)) Type 1 AIH((69)) Severe AIH((70,72)) Predicts relapse after treatment((73)) Associated with poor outcome((70))”
BackgroundSelf-citationDiagnosis and treatment of autoimmune hepatitis
Czaja, A. J., & Freese, D. K. (2002) · Hepatology · doi:10.1053/jhep.2002.34944 · Cited by 563
Self-citationVergani, D., Alvarez, F., Bianchi, F. B., Cançado, E. L. R., Mackay, I. R., Manns, M. P., Nishioka, M., & Penner, E. (2004) · Journal of Hepatology · doi:10.1016/j.jhep.2004.08.002 · Cited by 446
“fact anti-SLA appears highly specific for the diagnosis of AIH, and its detection at the time of diagnosis identifies patients with more severe disease and a likely adverse outcome [46,49,50,52].”
Background
Metadata
- Authors
- Czaja, A.
- Venue
- The American Journal of Gastroenterology
- Published
- 2002-02
- Volume
- 97
- Issue
- 2
- Pages
- 413-419
- ISSN
- 0002-9270 (ISSN-L)
- OpenAlex
- W2064602088
- Cited by
- 142
- References
- 2
- FWCI
- 4.70
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Antibodies to soluble liver antigen/liver pancreas and HLA risk factors for type 1 autoimmune hepatitis. https://app.cochat.ai/papers/10.1016/s0002-9270(01)04041-2
- The paper
- Czaja, A. (2002). Antibodies to soluble liver antigen/liver pancreas and HLA risk factors for type 1 autoimmune hepatitis. The American Journal of Gastroenterology. https://doi.org/10.1016/s0002-9270(01)04041-2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.